Revive Therapeutics Begins Laying Groundwork For Commercialization Of Bucillamine

Revive Therapeutics (CSE: RVV) this afternoon reported that it is in the process of pursuing a commercialization plan for the use of Bucillamine in the treatment of Covid-19. The process follows the continued success of phase 3 clinical trials being conducted by the firm.

With respect to the clinical trials, the company is currently continuing with its phase three study. There are two remaining interim analysis timepoints in the study, which are 600 and 800 patients, for which the company has to collect safety and efficacy data on the drug. To date no adverse events or safety concerns have occurred under the trials.

Once each milestone is achieved, the company is to meet with the Independent Data and Safety Monitoring Board for review of the results, with such meetings expected to occur in the third quarter. The company has indicated that as of late, the board has suggested that the firm proceed with a 600 mg high dose of the drug for the remainder of the study.

The company this morning also indicated that following meetings with the board, the firm is prepping for the potential filing of an Emergency Use Authorization with the US Food and Drug Administration. Such a filing will be made if the clinical trials provide evidence to the board to recommend such an authorization.

“We have made tremendous progress over the last few months by engaging over 40 clinical sites and completing patient enrollment to meet its completed and future DSMB interim analysis timepoints which will allow for the Study to continue and to have potential to seek EUA approval from the FDA. We are continuing to add to our clinical site roster in the U.S. and patient enrollment that would expedite the completion of the Phase 3 study.”

Michael Frank, CEO

Finally, Revive is in the midst of discussions with pharmaceutical firms at an international level that are looking to acquire the rights for Bucillamine as a treatment against Covid-19 in several jurisdictions. The development has lead to the pursuit of a commercialization plan that would be based on the success of the phase 3 clinical trial.

Revive Therapeutics last traded at $0.56 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Revive Therapeutics Appoints Airway Disease Expert As Advisor For COVID-19 Phase 3 Study

Revive Therapeutics (CSE: RVV) has strengthened its scientific and advisory team as it looks to...

Thursday, December 31, 2020, 07:39:28 AM

The Deep Dive Compiles Company Profile on Revive Therapeutics

The Deep Dive has assembled a company profile for that of Revive Therapeutics (CSE: RVV),...

Tuesday, May 19, 2020, 02:30:25 PM

Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury

Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a...

Friday, March 19, 2021, 07:47:09 AM

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an...

Thursday, April 22, 2021, 08:18:53 AM

Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study

Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase...

Friday, February 26, 2021, 08:54:19 AM